Kevin Langridge

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology. Based in Surrey, UK, the company's shares trade on the AIM market of the London Stock Exchange. Futura's development pipeline focuses on sexual healthcare and pain relief management and we are evaluating further therapeutic opportunities as potential additions to the pipeline. Futura is gaining recognition within the pharmaceutical industry for its strengths in transdermal drug delivery technology. We have a number of relationships with key players.